J&J, AstraZeneca explore Covid-19 vaccine modification after blood clot reports
Coronavirus chronicle
13 July, 2021, 05:10 pm
Last modified: 13 July, 2021, 05:10 pm
Vials of Johnson & Johnson's Janssen coronavirus disease (COVID-19) vaccine candidate are seen in an undated photograph. Johnson & Johnson/Handout via REUTERS.
Johnson & Johnson and AstraZeneca are conducting early-stage research into whether potential modifications to their Covid-19 vaccines could reduce or eliminate the risk of rare but serious blood clots linked to the shots, the Wall Street Journal reported, citing people close to the process.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.